Perspective Therapeutics (CATX) said Tuesday it has treated the first patient in a phase 1/2a dose-finding trial to evaluate the safety and initial anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha.
Patient selection is based on single-photon emission computed tomography, or SPECT imaging using [203Pb]PSV359, the company said.
Fibroblast activation protein alpha is a protein commonly found on the surface of cancer-associated fibroblasts in the stroma, a component of the tumor microenvironment in most epithelial cancers, the company said.
Shares of Perspective Therapeutics were down more than 2% in recent Tuesday trading.
Price: 2.40, Change: -0.06, Percent Change: -2.24
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。